Laddar populära aktier...
(Stockholm, Sverige, 20 november 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för det tredje kvartalet 2024 nu finns til...
(Stockholm, Sweden, 20 November, 2024) Inhalation Sciences AB announces that its Q3 Report for 2024 is now available on the company's websit...
(Stockholm, 16 October 2024) Inhalation Sciences Sweden AB (ISAB) today releases the latest update on progress in its FDA BAA (Broad Agency ...
A new publication demonstrates how XposeALI[®], Inhalation Sciences’ in vitro cell-based exposure module, successfully predicted the toxicit...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 4 september 2024 extra bolagsstämma.
(Stockholm, Sweden, 28 August 2024) Inhalation Sciences AB announces that its Q2 Report for 2024 is now available on the company’s website.
(Stockholm, Sverige, 28 augusti 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2024 finns nu tillgängl...
Aktieägarna i Inhalation Sciences Sweden AB (publ), org.
(Stockholm, 15 August 2024) Inhalation Sciences AB (ISAB) has received a surge of new orders, primarily for its Inhalation Research Services...
Inhalation Sciences Sweden AB’s (publ) (“Inhalation Sciences” or the “Company”) Nomination Committee proposes that Ulf Ericsson be elected a...
(Stockholm, 13 June 2024) Inhalation Sciences AB (ISAB) has received its first order for a preclinical dissolution study using its high-prec...
Inhalation Sciences CEO Manoush Masarrat discusses the company’s recent Q1 Report, and takes investors’ questions, in the first of a new reg...
(Stockholm, Sweden, 28 May 2024) Inhalation Sciences AB announces that its Q1 Report for 2024 is now available on the company’s website.
(Stockholm, Sverige, 28 maj 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2024 finns nu tillgänglig ...
On 20 May Inhalation Sciences AB CSO Per Gerde presented the company’s predictive tools for developing and assessing generic inhaled pharmac...
Inhalation Sciences AB (ISAB) has received a purchase order worth 60,000 EURO (almost 700,000 SEK) from a returning customer – one of the wo...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 14 maj 2024 årsstämma i Huddinge.
Inhalation Sciences AB announces that its Annual Report for 2023 is now available on the company’s website.
Inhalation Sciences AB meddelar att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida.
Inhalation Sciences Sweden AB (ISAB) has been invited to provide a public comments presentation at the FDA’s public workshop GDUFA (Generic ...
I ISAB’s bokslutskommuniké för 2023 publicerad den 28e februari 2024, har intäkten från Aprinha projektet redovisats som nettoomsättning.
(Stockholm, 11 March 2024) Positive results from Inhalation Sciences’ first-in-human clinical study of its aerosol generating system Precise...
(Stockholm, Sverige, 29 februari 2024) Inhalation Sciences AB meddelar att bolagets delårsrapport för fjärde kvartalet 2023 nu finns tillgän...
(Stockholm, Sweden, 28 February 2024) Inhalation Sciences AB announces that its Q4 / Year End Report for 2023 is now available on the compan...
Inhalation Sciences AB (ISAB) has signed a new partnership with fellow European inhalation development service provider Actarmo Medical GmbH...
(Stockholm, Sweden, 29 December,2023) Inhalation Sciences AB (ISAB) has secured a product service contract with a worth of 47,000 Euro on it...
(Stockholm, Sweden, 13 December 2023) Interest and interaction was high on December 11 at ISAB’s latest industry webinar, ‘Inhaled Biologics...
(Stockholm, Sverige, 22 november 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2023 nu finns tillgän...
(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q3 Report for 2023 is now available on the company’s website.
Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.
(Stockholm, Sweden, 13 November,2023) Inhalation Sciences AB has received a new purchase order worth 276,450 Euro from a returning customer,...
(Stockholm, Sweden, 8 November,2023) Inhalation Sciences AB has signed a new order valued at 54,700 Euro with a customer in Europe developin...
Join Inhalation Sciences AB (ISAB) CEO Manoush Masarrat for a 2-minute company pitch and 20-minute analyst Q&A at the livestreamed Redeye Li...
(Stockholm, October 18, 2023) Innovative Swedish MedTech company Inhalation Sciences Sweden AB (ISAB) has strengthened its IP portfolio in t...
Inhalation Sciences AB (ISAB) has been awarded a new order from a returning customer for an Inhalation Research Services (IRS) project.
Inhalation Sciences AB (ISAB) has signed a collaboration agreement with a leading Indian multinational pharma company with a powerful respir...
(Stockholm, Sweden, 29 August,2023) Inhalation Sciences AB announces that its Q2 Report for 2023 is now available on the company’s website.
(Stockholm, Sverige, 29 augusti 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2023 nu finns tillgängl...
(Stockholm, Sweden, 23 August 2023) Inhalation Sciences AB will repay a 1.
Inhalation Sciences Sweden AB:s (publ) (”Inhalation Sciences” eller “Bolaget”) styrelseledamot Mårten Winge har idag meddelat sin avsikt att...
Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) som avslutades den 9 maj 2023 har slutregistrerats.
The rights issue in Inhalation Sciences Sweden AB (publ) ("ISAB" or the "Company") which ended on May 9, 2023 has been finally registered.
Inhalation Sciences AB (ISAB) has received a new Purchase Order worth 94,000 USD, or just over 1 million SEK, from a distributor in Asia, th...
Inhalation Sciences AB (ISAB) has received a Purchase Order, worth 125.
Inhalation Sciences AB (ISAB) has received a new order for an Inhalation Research Services (IRS) project using its predictive preclinical te...
The rights issue in Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) has been partially registered with the Swedish Companies ...
Företrädesemissionen i Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har delregistrerats vid Bolagsverket och betalda teckna...
(Stockholm, Sweden, 31 May 2023) Inhalation Sciences AB announces that its Q1 Report for 2023 is now available on the company’s website.
(Stockholm, Sverige, 31 maj 2023) Inhalation Sciences AB meddelar att bolagets delårsrapport för första kvartalet 2023 nu finns tillgänglig ...
(Stockholm, 25 May, 2023) Inhalation Sciences (ISAB) has been awarded 125,000 EURO for its role in the research project ‘New Inhalation Form...
Inhalation Sciences AB (ISAB) has received a new order worth 53,000 Euro from a regular client – a large global player in the field of inhal...
Inhalation Sciences Sweden AB (publ) (“ISAB” or the ”Company”) today announces the outcome of the rights issue of shares that the Company an...
Inhalation Sciences Sweden AB (publ) (“ISAB” eller ”Bolaget”) offentliggör idag utfallet av den företrädesemission av aktier som Bolaget off...
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 12 maj 2023 årsstämma i Huddinge.
Today on May 9, 2023, is the last day for participation in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of ...
Idag, den 9 maj är sista dag för deltagande i Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av aktier (...
(Stockholm, 05 May 2023) Following its communication on April 18, 2023, regarding completion of the required administrative routines necessa...
(Stockholm, Sweden, 4 May 2023) Almost 200 specialists registered for ISAB’s latest experts’ webinar, now available to view online on ISAB’s...
2023 has started in line with our expectations and we continue to see a steady inflow of inquiries from various biopharma customers and good...
Today on April 24, 2023, the subscription period begins in Inhalation Sciences Sweden AB (publ)’s ("ISAB" or the "Company") rights issue of ...
Idag, den 24 april 2023, inleds teckningsperioden för Inhalation Sciences Sweden AB (publ):s (”ISAB” eller ”Bolaget”) företrädesemission av ...
Inhalation Sciences Sweden AB (publ) (“ISAB” or the “Company”) today publishes the information memorandum prepared in connection with the Co...
Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) offentliggör idag det informationsmemorandum som upprättats med anledning av B...
(Stockholm, Sweden, 19 April 2023) Following its highly successful webinar on DissolvIt dissolution studies on March 30[th] – 300 people reg...
(Stockholm, 18 April 2023) Inhalation Sciences Sweden AB (ISAB) has completed all the required administrative routines necessary to proceed ...
(Stockholm, Sverige, 11 april 2023) Inhalation Sciences AB meddelar att en uppdaterad Årsredovisning 2022, inklusive revisionsberättelsen, ä...
(Stockholm, Sweden, 11 April 2023) Inhalation Sciences AB announces that it is now releasing an updated version of its Annual Report 2022 th...
(Stockholm, Sverige, 11 april 2023) Inhalation Sciences AB meddelar att bolagets Årsredovisning 2022 nu finns tillgänglig på bolagets hemsid...
(Stockholm, Sweden, 11 April 2023) Inhalation Sciences AB announces that its Annual Report for 2022 is now available on the company’s websit...
The Board of Directors of Inhalation Sciences Sweden AB (publ) (”ISAB” or the ”Company”) has with the support of the authorization from the ...
Styrelsen för Inhalation Sciences Sweden AB (publ) (”ISAB” eller ”Bolaget”) har, med stöd av bemyndigande från årsstämman den 6 maj 2022, be...
Inhalation Sciences AB (ISAB) has received an order from a new client, a global generics company, for an Inhalation Research Services (IRS) ...
Inhalation Sciences will take part in the Stockholm Corporate Finance 15th Life Science Capital Markets Days on 8 - 9 March 2023 at IVA Conf...
Inhalation Sciences deltar på Stockholm Corporate Finance 15:e Life Science Kapitalmarknadsdagar den 8 - 9 mars 2023 på IVA konferenscenter ...
(Stockholm, Sweden, 7 March 2023) On 7 February 2023 Inhalations Sciences AB (ISAB) announced that a returning US client had paid a 50,000 E...
(Stockholm, Sweden, 28 February 2023) Inhalation Sciences AB announces that its Year-End Report for 2022 is now available on the company’s w...
(Stockholm, Sverige, 28 februari 2023) Inhalation Sciences AB meddelar att bolagets bokslutskommuniké 2022 nu finns tillgänglig på bolagets ...
A returning US client of Inhalation Sciences AB (ISAB) will pay a 50,000 Euro deposit to book lab time and facilities in April 2023 for an I...
Inhalation Sciences AB (ISAB) has received an order worth over 914,000 SEK (81,200 Euros) for an Inhalation Research Service (IRS) project f...
(Stockholm, Sweden, 12 January 2023) Post your questions to ISAB CEO Manoush Masarrat and Chairman Daniel Spasic for their joint Redeye even...
Inhalation Sciences AB (ISAB) has signed a new R&D contract worth 257,000 SEK (23,200 Euros) for Inhalation Research Services (IRS) work for...
Inhalation Sciences AB (ISAB) has received an order worth 1.
At this year’s DDL in Edinburgh, Scotland (7-9 December) Inhalation Sciences AB (ISAB) presented, for the first time, data from its clinical...
(Stockholm, Sweden, 22 November 2022) Inhalation Sciences AB announces that its interim report for the third quarter 2022 is now available o...
(Stockholm, Sverige, 22 november 2022) Inhalation Sciences AB meddelar att bolagets delårsrapport för tredje kvartalet 2022 nu finns tillgän...
(Stockholm, 14 November 2022) In September 2022 Inhalation Sciences Sweden AB (ISAB) was awarded an FDA BAA (Broad Agency Announcement) cont...
Inhalation Sciences has signed a new contract worth 1.
(Stockholm 18 October 2022) Inhalation Research Services (IRS) has received a revised order increasing the amount that it will be paid by a ...
Inhalation Research Services (IRS) has signed a new contract worth 806,000 SEK with a returning customer for a new in vivo study.
With over 30 years in the life science and pharma industries and deep roots in respiratory, Inhalation Sciences' new Board member Jan Hellqv...
(Stockholm 20 September 2022) ISAB’s conference paper on its study validating PreciseInhale[®] for clinical use has been accepted by the Dru...
(Stockholm, 16 September 2022) Inhalation Sciences AB (ISAB) has received a new order from prestigious returning client the Department of Ph...
ISAB’s contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.
(Stockholm, 15 September 2022) Inhalation Sciences Sweden AB has been granted a BAA contract for dissolution research purposes.
Inhalation Sciences Sweden AB (publ) (”Bolaget”) avhöll den 5 september 2022 extra bolagsstämma.
(Stockholm, 5 September 2022) Inhalation Sciences AB (ISAB) has received a purchase order worth 360,000 SEK for development and required sof...
(Stockholm, Sweden, 29 August 2022) Inhalation Sciences AB announces that its interim report for the second quarter 2022, January 1 – June 3...
(Stockholm, Sverige, 29 augusti 2022) Inhalation Sciences AB meddelar att bolagets delårsrapport för andra kvartalet 2022 nu finns tillgängl...
